Sign in or create an account to add this stock to your watchlist.
About Biohaven Pharmaceutical (NYSE:BHVN)
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases. In addition, it develops BHV-3500 for the acute treatment and prevention of migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. The company was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:BHVN
CUSIPN/A
Phone203-404-0410
Debt
Debt-to-Equity RatioN/A
Current Ratio6.80
Quick Ratio6.80
Price-To-Earnings
Trailing P/E Ratio-8.17
Forward P/E Ratio-6.04
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.66 per share
Price / Book11.17
Profitability
EPS (Most Recent Fiscal Year)($5.00)
Net Income$-127,190,000.00
Net MarginsN/A
Return on Equity-137.13%
Return on Assets-120.17%
Miscellaneous
Employees42
Outstanding Shares38,880,000
Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions
What is Biohaven Pharmaceutical's stock symbol?
Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."
How were Biohaven Pharmaceutical's earnings last quarter?
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) posted its quarterly earnings results on Tuesday, May, 15th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by $1.21. View Biohaven Pharmaceutical's Earnings History.
When is Biohaven Pharmaceutical's next earnings date?
What price target have analysts set for BHVN?
7 brokers have issued 12 month target prices for Biohaven Pharmaceutical's shares. Their forecasts range from $25.00 to $48.00. On average, they expect Biohaven Pharmaceutical's stock price to reach $38.1667 in the next twelve months. View Analyst Ratings for Biohaven Pharmaceutical.
What are Wall Street analysts saying about Biohaven Pharmaceutical stock?
Here are some recent quotes from research analysts about Biohaven Pharmaceutical stock:
- 1. According to Zacks Investment Research, "Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. " (6/13/2018)
- 2. Canaccord Genuity analysts commented, "We await more details on the atogepant data. That said, we believe these early results bode well for the use of the oral anti-CGRP approach towards migraine prevention, as the data appear to hold their own against the competing injectable anti-CGRP biotech approach. At this time, our BHVN model and DCF-based price target of $40 continue to include no value for BHV-3500. These atogepant data, however, make us more optimistic that BHV-3500 could generate positive data as well over time, and we are reiterating our BUY rating on BHVN. Early days, but atogepant appears to hold its own vs. injectable products It is still very early and atogepant is yet to work in a full pivotal program." (6/11/2018)
- 3. Needham & Company LLC analysts commented, "Biohaven released financial results yesterday and we spoke w/ mgmt for an update. Top-line results from remaining Phase 3 Migraine trials of rimegepant (1-year safety trial and orally disintegrating tablet [ODT] trial) are still expected 4Q18. We expect data from these trials as well as from the ubrogepant open-label long-term extension trial later this yr to provide a more complete picture of safety and efficacy profiles. We currently view both the Biohaven and Allergan drugs as competitive, but acknowledge lower pain figures for rimegepant at 2hrs after administration. Mgmt is exploring partnership options for rimegepant, although we currently assume in our model that the drug will be commercialized by Biohaven. Reiterate BUY." (5/16/2018)
Who are some of Biohaven Pharmaceutical's key competitors?
Some companies that are related to Biohaven Pharmaceutical include Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Agios Pharmaceuticals (AGIO), Loxo Oncology (LOXO), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), FibroGen (FGEN), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Madrigal Pharmaceuticals (MDGL), Ultragenyx Pharmaceutical (RARE), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH) and Array Biopharma (ARRY).
Who are Biohaven Pharmaceutical's key executives?
Biohaven Pharmaceutical's management team includes the folowing people:
- Dr. Vladimir Coric, CEO & Director (Age 47)
- Mr. James Engelhart, Chief Financial Officer (Age 54)
- Dr. Charles Conway, Chief Scientific Officer (Age 56)
- Dr. Robert Berman, Chief Medical Officer (Age 55)
- Mr. John Tilton, Chief Commercial Officer (Age 50)
When did Biohaven Pharmaceutical IPO?
(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.
Has Biohaven Pharmaceutical been receiving favorable news coverage?
Media coverage about BHVN stock has been trending somewhat positive on Sunday, according to Accern. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biohaven Pharmaceutical earned a news sentiment score of 0.13 on Accern's scale. They also assigned media headlines about the company an impact score of 45.80 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Biohaven Pharmaceutical's major shareholders?
Biohaven Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.24%), VHCP Management II LLC (3.86%), Eagle Asset Management Inc. (2.98%), Foresite Capital Management IV LLC (2.36%), Eventide Asset Management LLC (0.89%) and Rock Springs Capital Management LP (0.90%). Company insiders that own Biohaven Pharmaceutical stock include Albert Cha, Declan Doogan, Gregory Bailey, James Engelhart, John Tilton, Kimberly Gentile, Portage Biotech Inc, Robert Berman and Vlad Coric. View Institutional Ownership Trends for Biohaven Pharmaceutical.
Which major investors are selling Biohaven Pharmaceutical stock?
BHVN stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Millennium Management LLC and Eagle Asset Management Inc.. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Gregory Bailey, James Engelhart, John Tilton, Kimberly Gentile, Portage Biotech Inc, Robert Berman and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical.
Which major investors are buying Biohaven Pharmaceutical stock?
BHVN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Foresite Capital Management IV LLC, Northern Trust Corp, ARS Investment Partners LLC, Sphera Funds Management LTD., Eventide Asset Management LLC, Rock Springs Capital Management LP and Schwab Charles Investment Management Inc.. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Albert Cha, James Engelhart and Robert Berman. View Insider Buying and Selling for Biohaven Pharmaceutical.
How do I buy shares of Biohaven Pharmaceutical?
Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biohaven Pharmaceutical's stock price today?
One share of BHVN stock can currently be purchased for approximately $40.87.
How big of a company is Biohaven Pharmaceutical?
Biohaven Pharmaceutical has a market capitalization of $1.59 billion. The company earns $-127,190,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Biohaven Pharmaceutical employs 42 workers across the globe.
How can I contact Biohaven Pharmaceutical?
Biohaven Pharmaceutical's mailing address is 234 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.
MarketBeat Community Rating for Biohaven Pharmaceutical (BHVN)
MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote "Outperform" if you believe BHVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Biohaven Pharmaceutical (NYSE:BHVN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Biohaven Pharmaceutical in the last 12 months. Their average twelve-month price target is $38.1667, suggesting that the stock has a possible downside of 6.61%. The high price target for BHVN is $48.00 and the low price target for BHVN is $25.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.86 | 2.83 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $38.1667 | $38.00 | $39.50 | $38.00 |
| Price Target Upside: | 6.61% downside | 25.45% upside | 30.58% upside | 73.28% upside |
Biohaven Pharmaceutical (NYSE:BHVN) Consensus Price Target History
Biohaven Pharmaceutical (NYSE:BHVN) Analyst Ratings History
Show:
(Data available from 6/17/2016 forward)
Biohaven Pharmaceutical (NYSE:BHVN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Biohaven Pharmaceutical (NYSE BHVN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 34.20%
Institutional Ownership Percentage: 77.29%
Biohaven Pharmaceutical (NYSE BHVN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/12/2018 | Robert Berman | Insider | Sell | 104,155 | $36.33 | $3,783,951.15 | |  |
| 6/7/2018 | Robert Berman | Insider | Sell | 25,845 | $36.01 | $930,678.45 | | |
| 6/5/2018 | Declan Doogan | Director | Sell | 89,216 | $35.25 | $3,144,864.00 | | |
| 6/5/2018 | Robert Berman | Insider | Sell | 6,362 | $36.02 | $229,159.24 | | |
| 6/1/2018 | Declan Doogan | Director | Sell | 110,784 | $35.03 | $3,880,763.52 | 463,913 | |
| 6/1/2018 | Vlad Coric | CEO | Sell | 50,000 | $35.02 | $1,751,000.00 | | |
| 5/30/2018 | Declan Doogan | Director | Sell | 842 | $35.00 | $29,470.00 | 463,913 | |
| 5/30/2018 | James Engelhart | CFO | Sell | 5,000 | $35.00 | $175,000.00 | 5,000 | |
| 5/30/2018 | Vlad Coric | CEO | Sell | 1,541 | $35.00 | $53,935.00 | | |
| 5/10/2018 | Robert Berman | Insider | Sell | 35,000 | $26.82 | $938,700.00 | | |
| 5/7/2018 | James Engelhart | CFO | Sell | 2,500 | $27.67 | $69,175.00 | | |
| 4/10/2018 | Robert Berman | Insider | Sell | 35,000 | $24.66 | $863,100.00 | | |
| 3/12/2018 | Robert Berman | Insider | Sell | 35,000 | $30.11 | $1,053,850.00 | | |
| 3/1/2018 | Kimberly Gentile | VP | Sell | 5,000 | $32.87 | $164,350.00 | | |
| 2/21/2018 | James Engelhart | CFO | Sell | 538 | $29.60 | $15,924.80 | 3,038 | |
| 2/12/2018 | Robert Berman | Insider | Sell | 35,000 | $30.42 | $1,064,700.00 | | |
| 2/1/2018 | Kimberly Gentile | VP | Sell | 5,000 | $32.78 | $163,900.00 | 5,000 | |
| 1/31/2018 | Gregory Bailey | Director | Sell | 50,000 | $33.71 | $1,685,500.00 | 2,516,701 | |
| 1/22/2018 | Gregory Bailey | Director | Sell | 49,000 | $30.76 | $1,507,240.00 | 2,583,289 | |
| 1/22/2018 | James Engelhart | CFO | Sell | 10,000 | $32.50 | $325,000.00 | 13,576 | |
| 1/19/2018 | Portage Biotech Inc. | Major Shareholder | Sell | 35,119 | $30.03 | $1,054,623.57 | | |
| 1/18/2018 | Declan Doogan | Director | Sell | 128,058 | $26.95 | $3,451,163.10 | 2,583,289 | |
| 1/16/2018 | Gregory Bailey | Director | Sell | 40,000 | $26.52 | $1,060,800.00 | | |
| 1/12/2018 | Declan Doogan | Director | Sell | 121,942 | $26.78 | $3,265,606.76 | | |
| 1/10/2018 | Declan Doogan | Director | Sell | 40,362 | $27.69 | $1,117,623.78 | | |
| 1/10/2018 | Robert Berman | Insider | Sell | 35,000 | $27.52 | $963,200.00 | | |
| 1/9/2018 | Portage Biotech Inc. | Major Shareholder | Sell | 84,881 | $30.06 | $2,551,522.86 | 6,278,504 | |
| 1/5/2018 | Portage Biotech Inc. | Major Shareholder | Sell | 22,996 | $30.03 | $690,569.88 | 6,278,504 | |
| 1/4/2018 | Gregory Bailey | Director | Sell | 50,000 | $28.71 | $1,435,500.00 | 1,187,275 | |
| 1/3/2018 | Portage Biotech Inc. | Major Shareholder | Sell | 35,650 | $28.61 | $1,019,946.50 | 124,371 | |
| 1/2/2018 | Kimberly Gentile | VP | Sell | 5,000 | $27.60 | $138,000.00 | 5,000 | |
| 12/20/2017 | Gregory Bailey | Director | Sell | 39,430 | $26.31 | $1,037,403.30 | 1,234,077 | |
| 12/19/2017 | Robert Berman | Insider | Sell | 10,000 | $24.10 | $241,000.00 | | |
| 12/11/2017 | Robert Berman | Insider | Sell | 25,000 | $21.28 | $532,000.00 | | |
| 12/1/2017 | Kimberly Gentile | VP | Sell | 5,000 | $21.99 | $109,950.00 | | |
| 11/30/2017 | Gregory Bailey | Director | Sell | 9,970 | $25.48 | $254,035.60 | 1,262,759 | |
| 11/27/2017 | Gregory Bailey | Director | Sell | 20,600 | $25.92 | $533,952.00 | 1,289,699 | |
| 11/24/2017 | Gregory Bailey | Director | Sell | 600 | $26.02 | $15,612.00 | 1,289,699 | |
| 11/14/2017 | Robert Berman | Insider | Sell | 160,000 | $25.76 | $4,121,600.00 | | |
| 11/10/2017 | James Engelhart | CFO | Sell | 30,538 | $26.58 | $811,700.04 | 25,176 | |
| 11/9/2017 | Robert Berman | Insider | Sell | 27,423 | $26.60 | $729,451.80 | | |
| 11/1/2017 | John Tilton | Insider | Sell | 30,000 | $29.25 | $877,500.00 | 30,000 | |
| 11/1/2017 | Kimberly Gentile | VP | Sell | 5,000 | $29.28 | $146,400.00 | 5,000 | |
| 11/1/2017 | Vlad Coric | CEO | Sell | 150,000 | $29.41 | $4,411,500.00 | | |
| 5/9/2017 | Albert Cha | Director | Buy | 470,000 | $17.00 | $7,990,000.00 | | |
| 5/9/2017 | James Engelhart | CFO | Buy | 2,500 | $17.00 | $42,500.00 | 3,576 | |
| 5/9/2017 | Robert Berman | Insider | Buy | 50 | $17.00 | $850.00 | | |
(Data available from 1/1/2013 forward)
Biohaven Pharmaceutical (NYSE BHVN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Biohaven to Present Key and Expanded Data from Phase 3 Clinical Trials of Rimegepant, its Oral CGRP Receptor Antagonist, During Four Late-Breaking Sessions at American Headache Society (AHS) Annual Scientific Meeting 2018
finance.yahoo.com - June 13 at 9:02 AM |
| Biohaven CEO Vlad Coric Named Ernst & Young Entrepreneur Of The Year 2018 Award Winner in New York Region
finance.yahoo.com - June 13 at 9:02 AM |
 | Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Robert Berman Sells 104,155 Shares
www.americanbankingnews.com - June 12 at 7:14 PM |
| Biohaven Pharmaceutical Holding Co Ltd (BHVN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 12 at 3:34 AM |
| Canaccord Genuity Reiterates $40.00 Price Target for Biohaven Pharmaceutical (BHVN)
www.americanbankingnews.com - June 11 at 6:04 PM |
| Biohaven Pharmaceutical (BHVN) Receives New Coverage from Analysts at Cantor Fitzgerald
www.americanbankingnews.com - June 11 at 5:32 PM |
| Biohaven Pharmaceutical Holding Co Ltd (BHVN) Forecasted to Earn FY2021 Earnings of ($8.00) Per Share
www.americanbankingnews.com - June 11 at 1:56 AM |
| Piper Jaffray Companies Analysts Give Biohaven Pharmaceutical (BHVN) a $48.00 Price Target
www.americanbankingnews.com - June 8 at 1:45 PM |
| Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Sells $229,159.24 in Stock
www.americanbankingnews.com - June 7 at 7:53 PM |
| Insider Selling: Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Sells 25,845 Shares of Stock
www.americanbankingnews.com - June 7 at 7:36 PM |
| Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Sells $3,144,864.00 in Stock
www.americanbankingnews.com - June 6 at 7:20 PM |
| Zacks: Analysts Expect Biohaven Pharmaceutical Holding Co Ltd (BHVN) Will Post Earnings of -$0.99 Per Share
www.americanbankingnews.com - June 6 at 3:14 AM |
| Insider Selling: Biohaven Pharmaceutical (BHVN) Director Sells 842 Shares of Stock
www.americanbankingnews.com - June 1 at 8:36 PM |
| Vlad Coric Sells 1,541 Shares of Biohaven Pharmaceutical (BHVN) Stock
www.americanbankingnews.com - June 1 at 8:34 PM |
| Vlad Coric Sells 50,000 Shares of Biohaven Pharmaceutical (BHVN) Stock
www.americanbankingnews.com - June 1 at 7:18 PM |
| Biohaven Pharmaceutical (BHVN) Director Declan Doogan Sells 110,784 Shares
www.americanbankingnews.com - June 1 at 7:18 PM |
| James Engelhart Sells 5,000 Shares of Biohaven Pharmaceutical (BHVN) Stock
www.americanbankingnews.com - May 30 at 7:32 PM |
| Biohaven Pharmaceutical's (BHVN) Buy Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - May 22 at 9:18 PM |
| Zacks: Analysts Anticipate Biohaven Pharmaceutical (BHVN) Will Post Earnings of -$0.99 Per Share
www.americanbankingnews.com - May 19 at 9:16 PM |
| Q3 2018 EPS Estimates for Biohaven Pharmaceutical Boosted by Analyst (BHVN)
www.americanbankingnews.com - May 18 at 7:56 AM |
| Biohaven Pharmaceutical (BHVN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 18 at 3:48 AM |
| Biohaven Pharmaceutical (BHVN) PT Set at $35.00 by Canaccord Genuity
www.americanbankingnews.com - May 17 at 6:36 PM |
| Biohaven Pharmaceutical (BHVN) Rating Reiterated by Needham & Company LLC
www.americanbankingnews.com - May 16 at 9:24 PM |
| Zacks Investment Research Downgrades Biohaven Pharmaceutical (BHVN) to Sell
www.americanbankingnews.com - May 16 at 6:36 PM |
| Biohaven Pharmaceutical (BHVN) Issues Quarterly Earnings Results, Misses Estimates By $1.20 EPS
www.americanbankingnews.com - May 16 at 1:18 PM |
| What Do Analysts Think About Biohaven Pharmaceutical Holding Company Ltd’s (NYSE:BHVN) Earnings Trend?
finance.yahoo.com - May 16 at 9:26 AM |
| Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results
finance.yahoo.com - May 15 at 5:03 PM |
| Robert Berman Sells 35,000 Shares of Biohaven Pharmaceutical (BHVN) Stock
www.americanbankingnews.com - May 14 at 7:41 PM |
| Biohaven Pharmaceutical (BHVN) CFO James Engelhart Sells 2,500 Shares
www.americanbankingnews.com - May 9 at 8:28 PM |
| Biohaven Pharmaceutical (BHVN) Raised to Hold at ValuEngine
www.americanbankingnews.com - May 3 at 10:32 PM |
| Zacks: Analysts Anticipate Biohaven Pharmaceutical (BHVN) Will Announce Earnings of -$0.89 Per Share
www.americanbankingnews.com - May 2 at 11:25 AM |
 | Allergan Hits Another Home Run For 2nd Migraine Study
seekingalpha.com - April 30 at 9:22 AM |
| Biohaven Pharmaceutical (BHVN) Given a $34.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - April 28 at 9:14 AM |
| FY2020 Earnings Estimate for Biohaven Pharmaceutical (BHVN) Issued By William Blair
www.americanbankingnews.com - April 26 at 11:28 AM |
| Biohaven announces secondary endpoint results from Phase 3 clinical trials BHV3000-301 and 302 of Rimegepant
seekingalpha.com - April 23 at 8:58 AM |
| Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phase 3 Trials in Acute Treatment of Migraine
finance.yahoo.com - April 23 at 8:58 AM |
| Biohaven Pharmaceutical (BHVN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 23 at 3:34 AM |
 | An Ear To The Pharma: 10 Stocks To Watch (BHVN, LLY, TOCA, ALDR.)
www.finanznachrichten.de - April 21 at 9:05 AM |
 | Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles
www.prnewswire.com - April 19 at 3:48 AM |
 | Commit To Purchase Biohaven Pharmaceutical Holding At $17.50, Earn 6.8% Annualized Using Options
www.nasdaq.com - April 18 at 4:55 PM |
| Biohaven Pharmaceutical (BHVN) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 17 at 7:34 PM |
| Short Interest in Biohaven Pharmaceutical (BHVN) Increases By 97.3%
www.americanbankingnews.com - April 17 at 1:37 AM |
| -$0.87 Earnings Per Share Expected for Biohaven Pharmaceutical (BHVN) This Quarter
www.americanbankingnews.com - April 15 at 11:15 AM |
| Insider Selling: Biohaven Pharmaceutical (BHVN) Insider Sells 35,000 Shares of Stock
www.americanbankingnews.com - April 12 at 7:17 PM |
| Biohaven Pharmaceutical (BHVN) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 10 at 12:03 AM |
| Biohaven Pharmaceutical (BHVN) PT Lowered to $36.00 at Needham & Company LLC
www.americanbankingnews.com - April 8 at 8:05 AM |
| Kleo Pharmaceuticals Selected to Present at Biotech Innovation Conference
finance.yahoo.com - April 5 at 4:37 PM |
| Biohaven Pharmaceutical (BHVN) Downgraded by Barclays to Equal Weight
www.americanbankingnews.com - April 5 at 11:32 AM |
| Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer
finance.yahoo.com - April 3 at 9:30 AM |
| Biohaven Pharmaceutical (BHVN) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:39 PM |
Biohaven Pharmaceutical (NYSE:BHVN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Biohaven Pharmaceutical (NYSE:BHVN) Income Statement, Balance Sheet and Cash Flow Statement
Biohaven Pharmaceutical (NYSE BHVN) Stock Chart for Sunday, June, 17, 2018
Loading chart…
